Cambridge, United Kingdom · Founded 2019 · Privately Held (backing)
Developer of allosteric small molecule inhibitors targeting MSH3/MutSbeta designed to treat Huntington's disease and other triplet repeat neurodegenerative disorders. LoQus23 Therapeutics is based in Cambridge, United Kingdom and was founded in 2019. Its last known valuation is $61.4 million. It has raised $67.2 million.
Last price · $/share
—
Implied valuation
$61.4M
Total raised
$67.2M
Last round
—
Cap table — not yet on record
LoQus23 Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of LoQus23 Therapeutics with a free account
·Watch LoQus23 Therapeutics: the Monday email on marks, rounds and moves
